Present-day trends in treatment of bacterial vaginosis
https://doi.org/10.21518/2079-701X-2018-7-106-111
Abstract
The most frequent infectious disease of the female reproductive system is bacterial vaginosis (BV). The increased interest in this nosology is explained by the clinical manifestation severity of the disease, rather than numerous data indicating the inextricable connection between BV and inflammatory diseases of female genitourinary system and the complications of pregnancy and delivery. The bacterial biofilm formation, which is found in 90% of cases, have been shown to provide bacteria with protection against antimicrobial agents, representing the specificity of the BV pathogenesis, which militates against the effectiveness of the treatment. The official guidelines recommend to use metronidazole and clindamycin as the first-line therapy for BV in Russia and abroad. However, the present-day concept of BV therapy provides for a comprehensive two-stage treatment with a wide range of combination drugs to eradicate BV-associated microorganisms. Due to the lack of a systemic effect, the preference should be given to combination drugs designed for local therapy. Tergynan is one of the most popular drugs used for topical BV therapy, which demonstrated clinical efficacy and ease of use. Analogue of Tergynan, ornidazole + neomycin + prednisolone + econazole is a topical drug with antibacterial, antifungal and anti-inflammatory components, but has more modern antibacterial (ornidazole) and antifungal (econazole) components. The Russian studies showed convincing efficacy, safety and ease of use of a drug containing ornidazole + neomycin + prednisolone + econazole in BV therapy, which makes it possible to recommend it for practical use.
About the Authors
E. V. Lisovskaya
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of RF
Russian Federation
Russian Federation
E. G. Khilkevich
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of RF
Russian Federation
MD
Russian Federation
MD
References
1. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am. J. Obstet. Gynecol., 2013, 209(6): 505-523.
2. Savicheva AM, Tapilskaya NI, Shipitsina EV, Vorob’eva NE. Bacterial vaginosis and aerobic vaginitis as the main imbalances of the vaginal microflora. Features of diagnostics and treatment. Akusherstvo i Ginekologiya, 2017, 5: 24-31.
3. Mawzjutov AR. Bacterial vaginosis: etiopathogenetic aspects. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii, 2007, 6: 93-100.
4. Patterson JL, Stull-Lane A, Girerd PH, Jefferson KK. Analysis of adherence, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginalis relative to other bacterial-vaginosis-associated anaerobes. Microbiology, 2010 Feb, 156(Pt 2): 392-399.
5. Tikhomirov AL, Sarsaniya SI. The modern features of bacterial vaginosis: is it so simple? Shkola Klinitsista, 2010, 31: 536.
6. Titov VN. Lipopolysaccharides of gram-negative bacteria as exogenous pathogens. The translocation of bacteria in vivo, inflammation and pathology of the cardiovascular system. Klinicheskaya Laboratornaya Diagnostika, 2005, 8: 23-38.
7. Serov VN. Rational therapy for vaginal infections. Ginekologiya, 2005, 7: 115-118
8. Donders G, Bellen G, Rezeberga D. Aerobic vaginitis in pregnancy. BJOG, 2011, 118(10): 1163-1170.
9. Rezeberga D, Lazdane G, Kroica J, Sokolova L, Donders GG. Placentalhistological inflammation and reproductive tract infections in a low risk pregnant population in Latvia. Acta Obstet. Gynecol. Scand., 2008, 87(3): 360-365.
10. Sherrard J, Donders G, White D. European (IUSTI/ WHO) Guideline on the manage-ment of vaginal discharge. Int J STD AIDS, 2011, 22: 421-429.
11. Rogovskaya SI. Practical colposcopy. M.: GEOTAR-MEDIA, 2010, 232
12. Boyle DC, Barton SE, Uthayakumar S, Hay PE, Pollock JW, Steer PJ, Smith JR, Boyle DC, Barton SE, Uthayakumar S, Hay PE, Pollock JW, Steer PJ, Smith JR. Is bacterial vaginosis associated with cervical intraepithelial neoplasia? Int J Gynec Cancer, 2003, 13: 2: 159-163.
13. Vetrano G, Pacchiarotti A, Lombardi G, Cimellaro V, Verrico M,Carboni S, Corosu R. Correlation between squamous intraepithelial lesions (SILs) and bacterial vaginosis. Eur J Gynaec Oncol, 2007, 28: 4: 310-312.
14. Woods JL, Bailey SL, Hensel DJ, Scurlock AM. Cervicitis in adolescents: do clinicians understand diagnosis and treatment? J Pediatr Adolesc Gynec, 2011, 24: 6: 359-364.
15. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol, 1991, 29: 297-301.
16. Chalepo KV, Nazarova VV, Menukhova YuN et al. Estimation of modern methods of laboratory diagnosis of bacterial vaginosis. Zhurnal Akusherstva i Zhenskikh Bolezney, 2014, LXIII (1): 26-32.
17. Rumyantseva TA, Bellen G, Romanuk TN et al. Utility of microscopic techniques and quantitative real-time polymerase chain reaction for the diagnosis of vaginal microflora alterations. J Low Genit Tract Dis, 2015, 19(2): 124-128.
18. Malova IO, Rahmatulin MR, Sokolovsky EV, Savicheva AM. Federal Clinical Guidelines for Management of Patients with Bacterial Vaginosis, 2013
19. Workowski K, Berman S. Sexually transmitted diseases treatment guidelines 2010. MMWR, 2010, 59(RR12): 1-110.
20. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL Jr, Martin DH. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis, 2004, 4: 5.
21. De Backer E, Dubreuil L, Brauman M, Acar J, Vaneechoutte M. In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved inbacterial vaginosis. Clin Microbiol Infect, 2010, 16(5): 470-472.
22. Bahar H, Torun MM, Oçer F, Kocazeybek B. Mobiluncus species in gynaecological and obstetric infections: antimicrobial resistance and prevalence in a Turkish population. Int J Antimicrob Agents, 2005, 25(3): 268-271.
23. Lavrova LV. Diaghilev NI, Karpova EE. Experience in managing bacterial vaginosis. Akusherstvo i Ginekologiya, 2017, 10: 120-123.
24. Shipitsina EV, Khusnutdinova TA, Ryzhkova OS, Kryasanova AA, Budilovskaya OV, Rybina EV, Vorobyeva NE, Savicheva AM, Gushchin AE. Comparison of the effectiveness of bacterial vaginosis diagnosis according to clinical signs and the laboratory findings. Zhurnal Akusherstva I Zhenskikh Bolezney, 2016, 4: 76-82.
25. Karatyuk TI. Experience in using a combination drug containing neomycin, nystatin, predniso-lone, ternidazole for the treatment of inflammatory diseases of the female lower genital organs. Rossiyskiy Vestnik Akushera-Ginekologa, 2012, 6: 76-80.
26. Rakhmatulina MR. Experience in using 5-nitroimidazoles for the treatment of patients with bacterial vaginosis. Rossiyskiy Vestnik Akushera-Ginekologa, 2015, 2: 92-97.
27. Kuznetsova YuN. Efficacy of Dazolic (ornidazole) in the treatment of bacterial vaginosis. Klinicheskie Issledovaniya, 2009, 3: 40-45.
28. Letyaeva OI, Ziganshin OR. The role of local therapy in correcting genitourinary microbiocenosis in women of reproductive age. Yuzhno-Uralskiy Meditsinskiy Zhurnal, 2014, 2: 35-40.
29. Modern diagnosis and treatment of vaginal infections in the projection of outpatient treatment. New developments in the practice of a doctor. The 2nd All-Russian Seminar Reproductive Potential of Russia: Versions and Contraversions. Moscow Readings. Effektivnaya Farmakoterapiya, 2017, 26: 46-50.
30. Topical issues of urology: a collection of scientific works of the 5th Congress of Urologists of Siberia with international participation, Krasnoyarsk, May 13-14, 2016: 58-60.
Review
For citations:
Lisovskaya EV, Khilkevich EG. Present-day trends in treatment of bacterial vaginosis. Meditsinskiy sovet = Medical Council. 2018;(7):106-111. (In Russ.) https://doi.org/10.21518/2079-701X-2018-7-106-111
Views:
1134
Email this article 